Local delivery of E2F decoy oligodeoxynucleotides using ultrasound with microbubble agent (Optison) inhibits intimal hyperplasia after balloon injury in rat carotid artery model

被引:70
作者
Hashiya, N
Aoki, M
Tachibana, K
Taniyama, Y
Yamasaki, K
Hiraoka, K
Makino, H
Yasufumi, K
Ogihara, T
Morishita, R [1 ]
机构
[1] Osaka Univ, Grad Sch Med, Div Clin Gene Therapy, Suita, Osaka 565, Japan
[2] Osaka Univ, Grad Sch Med, Dept Geriatr Med, Suita, Osaka 565, Japan
[3] Osaka Univ, Grad Sch Med, Div Gene Therapy Sci, Suita, Osaka 565, Japan
[4] Fukuoka Univ, Sch Med, Dept Anat 1, Hakata, Japan
关键词
E2F; restenosis; decoy; ultrasound; blood vessel; echo-contrast microbubble agent; Optison;
D O I
10.1016/j.bbrc.2004.03.070
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Since restenosis after angioplasty still remains a major clinical problems, inhibition of neointimal formation is an important subject. In this study, we focused on the transcription factor, E2F, that plays a pivotal role in the transactivation of cell-cycle regulatory genes, and also we developed a newly delivery system of decoy oligodeoxynucleotides (ODN). We transfected E2F decoy ODN mixed with an echo-contrast microbubble agent (Optison) into rat carotid artery balloon-injured model by using therapeutic ultrasound (US) to inhibit neointimal formation. Two weeks after transfection, the intimal to medial area ratio in E2F decoy + Optison + US group was significantly decreased (P < 0.01). Inhibition of cell growth was also confirmed by PCNA staining. No apparent toxicity such as inflammation could be detected in blood vessels transfected with E2F decoy ODN with Optison and ultrasound. Overall, the present studies demonstrated a novel non-viral ODN transfer method into blood vessels. A novel therapeutic strategy using E2F decoy ODN with Optison using ultrasound may be useful to inhibit restenosis in clinical practice without a viral vector. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:508 / 514
页数:7
相关论文
共 28 条
[1]   Restenosis: a challenge for pharmacology [J].
Bult, H .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2000, 21 (07) :274-279
[2]   CYTOSTATIC GENE-THERAPY FOR VASCULAR PROLIFERATIVE DISORDERS WITH A CONSTITUTIVELY ACTIVE FORM OF THE RETINOBLASTOMA GENE-PRODUCT [J].
CHANG, MW ;
BARR, E ;
SELTZER, J ;
JIANG, YQ ;
NABEL, GJ ;
NABEL, EG ;
PARMACEK, MS ;
LEIDEN, JM .
SCIENCE, 1995, 267 (5197) :518-522
[3]   Fusigenic viral liposome for gene therapy in cardiovascular diseases [J].
Dzau, VJ ;
Mann, MJ ;
Morishita, R ;
Kaneda, Y .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (21) :11421-11425
[4]   Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy [J].
Ehsan, A ;
Mann, MJ ;
Dell'Acqua, G ;
Dzau, VJ .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2001, 121 (04) :714-722
[5]  
Feldman L J, 1996, Semin Interv Cardiol, V1, P203
[6]  
GIBBONS GH, 1994, NEW ENGL J MED, V330, P1431
[7]   In vitro and in vivo transfection of plasmid DNA in the Dunning prostate tumor R3327-AT1 is enhanced by focused ultrasound [J].
Huber, PE ;
Pfisterer, P .
GENE THERAPY, 2000, 7 (17) :1516-1525
[8]   Gene therapy for attenuating cardiac allograft arteriopathy using ex vivo E2F decoy transfection by HVJ-AVE-liposome method in mice and nonhuman primates [J].
Kawauchi, M ;
Suzuki, J ;
Morishita, R ;
Wada, Y ;
Izawa, A ;
Tomita, N ;
Amano, J ;
Kaneda, Y ;
Ogihara, T ;
Takamoto, S ;
Isobe, M .
CIRCULATION RESEARCH, 2000, 87 (11) :1063-1068
[9]  
LEYEN HVL, 1995, P NATL ACAD SCI USA, V92, P1137
[10]  
LIBBY P, 1992, CIRCULATION, V86, P47